Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc. - Common Shares (NQ:XENE)

42.80 +0.37 (+0.87%)
Streaming Delayed Price Updated: 11:46 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xenon Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 Next >
News headline image
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Announces Proposed Public Offering
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Near the Top of Equities by Percentage Gain on 11/27
Via Investor Brand Network
News headline image
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
Conference call today at 8:30 am ET 
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency 
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Making Surprising Moves in Tuesday Session
Via Investor Brand Network
News headline image
Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder
Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ET 
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
News headline image
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.